Latest research on Tamoxifen

One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium. [PubChem]

Latest findings

Winder et al. [22] found that the T allele was associated with a better overall survival in colorectal cancer patients treated with cetuximab [33] and a better overall survival in ER-positive BC patients treated with Tamoxifen. rs2016347 is localized in the 3′-untranslated region of the IGF1R gene, functioning as a microRNA binding site [28]. [source, 2016]
This is the case for the anticancer drug Tamoxifen and other selective antiestrogen-binding site (AEBS) ligands such as tesmilifene, developed for the treatment of breast, lung, and prostate cancers (20–22), all of which have their antiproliferative and proapototic activities blocked by α-TP (23–27). [source, 2016]
α-TP has also been shown to inhibit the lipoperoxydation of cholesterol, blocking the production of the prodifferentiation and proapototic cholesterol-5,6-epoxides that have been identified as mediators of Tamoxifen activity in breast cancer cells (21, 26, 28, 29). [source, 2016]
These data suggest that the intake of α-TP during prophylactic or curative treatment could impair the clinical outcome of patients treated with Tamoxifen. [source, 2016]
Tamoxifen is a potent anticancer agent known to interrupt the enhanced estrogen activity of malignant mammary gland cells and approved by the U.S. [source, 2016]
Tamoxifen is the most widely prescribed anticancer drug across the globe. [source, 2016]
Tamoxifen benefits the breast cancer patients with an increase in overall survival, decreases in recurrence and the risk of contralateral disease. [source, 2016]
Tamoxifen has beneficial effects on bone density and lipid profiles. [source, 2016]
Tamoxifen antagonizes estrogen (E2)-regulated gene expression, and can promote the reexpression of E2-repressed genes and regulate the expression of E2-independent genes. [source, 2016]
Tamoxifen is most beneficial for younger women with an elevated risk of breast cancer. [source, 2016]